Characterization of RNA from Exosomes and Other Extracellular Vesicles Isolated by a Novel Spin Column-Based Method.
Enderle D, Spiel A, Coticchia CM, Berghoff E, Mueller R, Schlumpberger M, Sprenger-Haussels M, Shaffer JM, Lader E, Skog J, Noerholm M. · 2015
Read Characterization of RNA from Exosomes and Other Extracellular Vesicles Isolated by a Novel Spin Column-Based Method. by Enderle D, Spiel A, Coticchia CM, Berghoff E, Mueller R, Schlumpberger M, Sprenger-Haussels M, Shaffer JM, Lader E, Skog J, Noerholm M. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4552735.txt.
Introduction
Daniel Enderle leads a twelve-author team presenting a simpler way to harvest RNA from blood vesicles, in PLoS ONE in 2015. Cells shed tiny sacs called extracellular vesicles into blood, and the RNA inside them may serve as disease markers. The standard isolation route, hours of ultracentrifugation, is laborious and uneven between labs.
The team built a spin column kit that pulls vesicle RNA from up to 4 milliliters of serum or plasma. The yield matched or beat ultracentrifugation, with strong purity and a sharp preference for vesicle RNA over free-floating RNA. Rare transcripts stayed detectable thanks to the larger input volume. The method aims to make vesicle RNA studies reproducible enough for diagnostic use.
Catalog record
| CREATOR | Enderle D, Spiel A, Coticchia CM, Berghoff E, Mueller R, Schlumpberger M, Sprenger-Haussels M, Shaffer JM, Lader E, Skog J, Noerholm M. |
|---|---|
| YEAR | 2015 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Characterization of RNA from Exosomes and Other Extracellular Vesicles Isolated by a Novel Spin Column-Based Method By Daniel Enderle, Alexandra Spiel, Christine M Coticchia, Emily Berghoff, Romy Mueller, Martin Schlumpberger, Markus Sprenger-Haussels, Jonathan M Shaffer, Eric Lader, Johan Skog, Mikkel Noerholm, Gerrit J Bouma Published in: PLoS ONE DOI: 10.1371/journal.pone.0136133 ABSTRACT Abstract Exosomes and other extracellular vesicles (commonly referred to as EVs) have generated a lot of attention for their potential applications in both diagnostics and therapeutics. The contents of these vesicles are the subject of intense research, and the relatively recent discovery of RNA inside EVs has raised interest in the biological function of these RNAs as well as their potential as biomarkers for cancer and other diseases. Traditional ultracentrifugation-based protocols to isolate EVs are labor-intensive and subject to significant variability. Various attempts to develop methods with robust, reproducible performance have not yet been completely successful. Here, we report the development and characterization of a spin column-based method for the isolation of total RNA from EVs in serum and plasma. This method isolates highly pure RNA of equal or higher quantity compared to ultracentrifugation, with high specificity for vesicular over non-vesicular RNA. The spin columns have a capacity to handle up to 4 mL sample volume, enabling detection of low-abundance transcripts in serum and plasma. We conclude that the method is an improvement over traditional methods in providing a faster, more standardized way to achieve reliable high quality RNA preparations from EVs in biofluids such as serum and plasma. The first kit utilizing this new method has recently been made available by Qiagen as “exoRNeasy Serum/Plasma Maxi Kit”. INTRODUCTION Extracellular vesicles and their importance for molecular pathology Exosomes, microvesicles, and other extracellular vesicles have been understood to exist for more than 30 years ([1] and references within), but their potential for biomarker discovery and diagnostic development has been vastly underappreciated until recently [2–4]. Since the nomenclature of these vesicles is still being discussed [5], this article will collectively refer to exosomes and other extracellular vesicles as EVs. The majority of EVs are roughly 50–200 nm in diameter and known to form by two separate mechanisms. One pathway is through inward budding of endosomal membranes, which give rise to intracellular multivesicular bodies that later fuse with the plasma membrane, releasing the EVs to the exterior of the cell [1,6]. Alternatively, vesicles can be shed directly from the cell by outward budding of the plasma membrane [7,8]. In both cases, all EVs have a lipid bilayer surrounding the internal components, protecting them from enzymatic degradation and creating a naturally stable environment. Release of EVs from cells is an active process, and has been shown to provide a mechanism for cell-to-cell communication [9]. Tumor exosomes have been shown to mediate critical steps in the disease process, such as stimulation of angiogenesis [10] blunting the immune response [11,12] or even involvement in pre-metastatic niche formation [13]. Exosomes have also been shown to have important roles in normal physiology and pregnancy, where placental exosomes help to form an immunosuppressive barrier for the mother’s immune system [14,15]. As EVs are released during both normal and pathological conditions, their protein and lipid components have been extensively described [16,17]. However their nucleic acid components have only recently been the subject of study. EVs contain RNA [2,18] as well as DNA [19,20]. The RNA component of EVs is of particular diagnostic interest, as naked RNAs are not stable in blood outside of the vesicles, due to exposure to RNases [21]. Not all stable RNA in biofluids is contained within vesicles, however. There are miRNAs protected by protein complexes containing Ago2 [22–24] and some miRNAs have also been associated with HDL and LDL particles [25]. The RNA content of EVs has been described using RNA-seq, hybridization arrays and other screening methods, revealing the full spectrum of previously known transcript types. This includes miRNAs and other species of small non-coding RNAs (ncRNAs) like piRNAs, but also mRNAs, tRNAs, lncRNAs and rRNAs [26–28]. Moreover, there is intriguing evidence for vesicle-specific modification, enrichment, and isoforms of the enclosed RNA [2,26,29]. Reproducible RNA extraction from biofluids allows analysis of gene expression changes during disease. While mutation detection can be done at both the DNA and RNA level, many biomarkers are uniquely analyzed on the RNA. For example, transcriptional changes are measured at the RNA level, such as spatial or temporal deregulation of mRNA, miRNA, lncRNA and other non-coding RNAs. There are also disease specific splice variants (ARV-7 in prostate cancer [30], EGFRvIII in glioblastoma [31], BRAF variants in melanoma [32]) and larger deletions/fusions in intronic DNA regions that are more easily detected on the RNA level where the fusion site is defined, i.e. ALK fusions in lung cancer [33]. Thus, RNA analysis an attractive strategy for diagnostic development [34]. Here, the protective bilayer of EVs makes it possible to use both fresh and archived samples for RNA analysis; samples frozen for more than twelve years can still yield high-quality RNA ([2], S2 Fig). Development of biofluid-based biomarkers would limit the need for tissue biopsies and, with a simple non-invasive collection, enables longitudinal monitoring of health and disease. In Oncology, biofluids might also provide a more accurate representation of a tumor’s genetic makeup than a spatially restricted fine needle biopsy, including the heterogeneity of the primary tumor and of metastatic lesions [35,36]. Currently, there are methods to examine DNA-based biomarkers in biofluids, either by isolating circulating tumor cells (CTCs) or circulating cell-free DNA (cfDNA) [37]. Analyzing the genome of single CTCs allows to call somatic mutations [38], CTC abundance in blood is used for an FDA-cleared assay for cancer progression (CELLSEARCH) and cfDNA already allows to detect mutations in blood from a variety of cancers [39–41]. The development of RNA-based biofluid diagnostics utilizing EVs, however, is impeded by the lack of a standardized RNA isolation method with robust, reproducible performance. Current standard of RNA extraction from EVs Historically, the ‘gold standard’ for isolating EVs, and the enclosed RNA within, with good yield and quality has been differential ultracentrifugation. This is a time-consuming process, requiring a well-optimized protocol and significant capital investment. Unfortunately there is no standardization of these protocols, and laboratories are using different pre-processing protocols (i.e. generation of platelet poor plasma or removal of the “cell debris”) as well as different protocols for ultracentrifugation itself. Even where attempts are made to keep the spin times and centrifugal force constant, the pelleting efficiencies vary since different labs often use different rotors (with varying k-factors) and different sample dilutions steps [42]. These variables make comparison of results between studies virtually impossible and there is a need for more easily standardized methods. Due to such protocol discrepancies, the actual RNA content of EVs is still actively discussed. Development of a robust method that yields RNA in quality and quantity similar to ultracentrifugation has come to be recognized as an ideal solution, and many laboratories have endeavored to develop such a method, using a variety of approaches [43]. Methods using size-based filters (e.g. ExoMir, Biooscientific), antibody-based capture (e.g. Immunobeads, HansaBioMed), and polymer-based precipitation reagents [44] (e.g. Life Technologies, System Biosciences Inc.) are all available for researchers, providing varying degrees of utility. For example, kits developed with size-based